Seattle Genetics, Inc. (NASDAQ:SGEN)
| CAPS Rating |
|
|---|---|
| Open | $19.00 |
| Previous Close | $19.01 |
| Daily Range | $18.72 - $19.12 |
| 52-Week Range | $12.29 - $22.40 |
| Market Cap | $2.17B |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 863,915 |
| Average Daily Volume | 0 |
SGEN
VS S&P 500 (SPY)
How do you think SGEN will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
SGEN Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
SGEN News and Commentary
- Biotech Investors Confident: Industry Sees Big VC Spending in 2011 – The Motley Fool
- Warning: Don't Sell on This News – The Motley Fool
- The Magic Formula for Biotech – The Motley Fool
- FDA Warns On Serious Brain Infection Risk With Lymphoma Drug Adcetris – SmartMoney
- Don't Read Too Much Into This Partnership – The Motley Fool
- Are These Biotech Drug Launches Back on Track? – The Motley Fool
- JPMorgan Confab Kicks Off Biotech 2012 – Minyanville
- Biotech Ideas: Top Biotech Stocks with Bullish Institutional Trends – The Motley Fool
- What to Look For With Seattle Genetics in 2012 – The Motley Fool
- Health Care's Worst Stocks 2011: Dendreon – The Motley Fool
- ARIAD's Prolific 2011 – The Motley Fool
- Is Pharmacyclics the Perfect Stock? – The Motley Fool
- Why Biotech Investors Must Understand the FDA's Adverse Events Reports – Minyanville
- Health Care's 5 Worst November Flops – The Motley Fool
- Winners and Losers of Roche's Avastin Woes – The Motley Fool
- Seattle Genetics is Oversold, Analyst Says – Minyanville
- I Was Wrong About Dendreon – The Motley Fool
- How to Cut Your Taxes by $15 Million – The Motley Fool
- 5 Insider Stock Picks that Predictive Analysts Expect to Outperform – NASDAQ
- 5 Insider Stock Picks that Predictive Analysts Expect to Outperform – The Motley Fool
RSS Headlines
Fool UK
